The player is loading ...
Sign up to get updates from us
In this episode, VibeCast host Ray Dogum speaks with Frank Gleeson, Co-Founder and CEO of Satellos Bioscience, about groundbreaking small molecule therapies for Duchenne muscular dystrophy. -----------------------------------------------------------
Key moments: 00:00:05 - Introducing Satellos Bioscience 00:03:26 - Stem Cells and Duchenne Muscular Dystrophy 00:09:15 - Potential Treatment for Duchenne Muscular Dystrophy 00:13:22 - Research Discovery and Company Formation 00:15:59 - Clinical Trial Planning and Future Development 00:17:33 - Company Inflection Points 00:19:08 - Drug Impact and Potential 00:20:10 - Potential Indications 00:22:38 - Funding and Financial Strategy 00:24:35 - Biotech Ecosystem and Growth Guest Bio: During his career, Mr. Gleeson has been a key party to building more than 20 biomedical companies from breakthrough research and technologies and has negotiated numerous financing and M&A transactions valued in excess of $500 million. Prior to co-founding Satellos, he and Dr. Rudnicki co-founded Verio Therapeutics, where Mr. Gleeson was CEO and managed the acquisition by Fate Therapeutics (Nasdaq: FATE). Previous to Verio, he was Chief Commercial Operations at Centre for Probe Development and Commercialization (CPDC), where he played a principal role in building a global radiopharmaceutical manufacturing business and supporting the creation of two spin-out companies. Prior to CPDC, he served as an Executive-in-Residence with the Fight Against Cancer Innovation Trust (FACIT), an innovative nucleator, where he supported or led the creation, financing and exits of three new entities. Previously, Mr. Gleeson was founding CEO of MDS Proteomics Inc., where he made and integrated three acquisitions, built leading-edge sequencing infrastructure, a 200-person team, and raised in excess of $100 million. He was also Senior Vice President and Venture Partner with MDS Capital Corp. (now Lumira), where he was lead partner on a fund with more than $250 million under management focused on creating drug discovery companies based on novel Canadian science. Prior to his tenure with MDS, he enjoyed a 17-year operational career with ICI plc (now AstraZeneca), a global chemicals, pharmaceuticals, and advanced materials company, during which he was involved in technology commercialization in several fields both in Canada and internationally. Mr. Gleeson has served on numerous boards of private and public companies and not-for-profit entities. Guest Links: Linkedin: https://ca.linkedin.com/company/satellos-bioscience-inc Satellos Bioscience Twitter: https://twitter.com/satellosbio Satellos Bioscience Website: https://satellos.com/ About VibeCast VibeCast is our weekly informational podcast and content series exploring the hottest topics in drug development and Web3 with some of the dynamic people that make up the Vibe community. VibeCast is a collection of long-form and short-form video content intended to help our community learn about the current opportunities and challenges in biotech fundraising and community engagement innovation. Follow Vibe Bio's Socials: https://twitter.com/VibeBio https://www.linkedin.com/company/vibe-bio/ https://www.instagram.com/vibebiotechnology/ https://www.tiktok.com/@vibebio https://www.facebook.com/VibeBiotechnology/ Disclaimer: VibeCast is intended to be used for educational and entertainment purposes, and no information or opinions shared constitute advice or services. While guests are invited to listen, listeners acknowledge they are not being provided professional advice from the podcast or the guests. The podcast is for private non-commercial use and the statements of our guests reflect their personal views only and do not necessarily reflect the views or positions of any agency, organization, or company that they work for or are affiliated with.
